Real-world clinical characteristics, treatment patterns and outcomes in locally advanced or metastatic non-small cell lung cancer patients in Germany (I-O OPTIMISE/VONKO-014)

Recruiting

• Conditions: C34; Malignant neoplasm of bronchus and lung

• Registration Number: DRKS00031199
• Lead Sponsor: Bristol Myers Squibb

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-02-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50000

Inclusion Criteria

diagnosis years 2016-2022
- place of residence in respective federal state of cancer registry

Exclusion Criteria

patient is known to the cancer registry only by means of death certificate, a pathology report, a follow up notification, a tumor conference report or a combination of the aforementioned

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment patterns in patients with locally advanced or metastatic non-small cell lung tumor (LAM NSCLC) - from the time of diagnosis to the end of follow-up <br>(i) Description of the sequence of therapy options surgery, radiation, systemic anticancer therapy (chemotherapy, immunotherapy).<br>(ii) Classification of systemic anticancer therapy into lines of therapy according to the treatment guidelines for NSCLC.<br>For this purpose, the cancer registry data are used, which are recorded in a standardized form. For the scope and type of data collected, see the data set description in the Federal Gazette (Bundesanzeiger) 2021: BAnz AT 12.07.2021 B4

Secondary Outcome Measures

Name	Time	Method
Overall survival (a) from diagnosis and (b) from initiation of treatment with 9LA treatment to end of observation (=death or censoring [vital status alive at last linkage to registration offices in spring2022]).